Comparison of antibacterial activities of polymyxin B and colistin against multidrug resistant Gram negative bacteria
- 12 July 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Infectious Diseases
- Vol. 51 (9), 676-682
- https://doi.org/10.1080/23744235.2019.1640386
Abstract
Background: Polymyxin B and colistin have similar structures except for one amino acid. Usually, physicians choose either polymyxin B or colistin for treatment of infections caused by multidrug-resistant (MDR) organisms. The preference is based on previous experience. Not much data are found in the literature comparing the two drugs against the same microorganisms. In this study, we compared in vitro antimicrobial activities of the two polymyxins against a panel of highly resistant and susceptible microorganisms. Methods: Eighty-nine clinical isolates (27 Klebsiella pneumoniae, 31 Acinetobacter baumannii and 31 Pseudomonas aeruginosa) were tested in broth microdilution assays. Time-kill curve experiments were carried out on selected isolates. Results: Significantly lower MICs for polymyxin B than for colistin were found against all species tested including K. pneumoniae (p < .02), A. baumannii (p < .001) and P. aeruginosa (p < .01). The low MICs caused a change in categorical interpretations of only two K. pneumoniae and two P. aeruginosa. Similar results were obtained in time-kill curve experiments with both susceptible and resistant clinical isolates. Conclusions: Significantly lower MICs were found for polymyxin B against three of the most critical MDR species. Even though differences in categorical interpretations were not striking, lower MICs might be a critical consideration in clinical management of select cases where the concentration of these toxic antibiotics matters because of underlying co-morbidities. These results provide support to previous suggestions that re-consideration of breakpoint interpretations for polymyxins might be needed.Keywords
This publication has 22 references indexed in Scilit:
- ‘Old’ antibiotics for emerging multidrug-resistant bacteriaCurrent Opinion in Infectious Diseases, 2012
- Combating Antimicrobial Resistance: Policy Recommendations to Save LivesClinical Infectious Diseases, 2011
- In Vitro Evaluation of Antibiotic Synergy for Polymyxin B-Resistant Carbapenemase-Producing Klebsiella pneumoniaeJournal of Clinical Microbiology, 2010
- Looming Global-Scale Failures and Missing InstitutionsScience, 2009
- Polymyxins RevisitedClinical Microbiology Reviews, 2008
- Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxinsAnnals of Clinical Microbiology and Antimicrobials, 2007
- Comparison of Etest, Vitek and agar dilution for susceptibility testing of colistinClinical Microbiology & Infection, 2007
- Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 2006
- Difficulty in assaying colistin methanesulphonateClinical Microbiology & Infection, 2005
- Contemporary Assessment of Antimicrobial Susceptibility Testing Methods for Polymyxin B and Colistin: Review of Available Interpretative Criteria and Quality Control GuidelinesJournal of Clinical Microbiology, 2001